

WELCOMING PETER MUNYASI AS HEAD OF COMMERCIAL OPERATIONS AT BIO USAWA

November 11, 2024: Kigali, Rwanda and San Francisco, USA

We are thrilled to announce that Peter Munyasi has joined Bio Usawa as our new Head of Commercial Operations. With over two decades of experience in the pharmaceutical and healthcare sectors across Africa, Peter brings a wealth of expertise in commercial strategy, client relationship management, and digital healthcare marketing. His insights and commitment to health equity make him an invaluable addition to our team and our mission.

Peter's distinguished career includes pivotal roles at respected organizations such as Sanofi, Adcock Ingram, and Zuri Health. His recent accomplishments include launching innovative healthcare subscription services and developing digital wellness campaigns that have reached thousands across Kenya, showcasing his dedication to accessible healthcare solutions. Known for his strategic acumen, Peter will be instrumental in expanding Bio Usawa's footprint across Africa, starting with Kenya.

At Bio Usawa, we believe in building a healthier future, by Africans, for Africans. Peter's leadership and passion for advancing access to essential medicines align seamlessly with our vision to deliver affordable, life-saving biologics to communities across the continent. We are confident that his contributions as Head of Commercial Operations will greatly enhance our mission of achieving health equity for all.

Please join us in welcoming Peter Munyasi to the Bio Usawa family as he embarks on this impactful journey with the scintillating belief that "True progress in healthcare is measured not by the discovery of new cures, but by the reach of those cures to all who need them."

About Bio Usawa Inc.

Bio Usawa Inc. is at the forefront of transforming healthcare access across Africa through the local production and distribution of affordable monoclonal antibodies. With a profound commitment to public health, BUI aims to become the leading supplier of therapeutic monoclonal antibodies in Africa, ensuring no patient is left without essential treatments due to cost barriers.



**WHEN PATIENTS DIE BECAUSE THERE IS NO CURE, IT'S A TRAGEDY; WHEN THEY DIE EVEN WHEN
THERE IS AN EFFECTIVE CURE BECAUSE OF THE COST, IT IS INJUSTICE.**